Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Infection, Human Immunodeficiency Virus I

Conditions

Infection, Human Immunodeficiency Virus I

Trial Timeline

Feb 1, 2011 → Dec 3, 2015

NCT ID

NCT01263015

About Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo

Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus I. The current trial status is completed. This product is registered under clinical trial identifier NCT01263015. Target conditions include Infection, Human Immunodeficiency Virus I.

What happened to similar drugs?

20 of 20 similar drugs in Infection, Human Immunodeficiency Virus I were approved

Approved (20) Terminated (3) Active (0)

✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved

✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved

✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved

✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved

✅Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved

✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved

✅Lopinavir/RitonavirAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01263015	Phase 3	Completed	Feb 1, 2011	Dec 3, 2015	Infection, Human Immunodeficiency Virus I

Competing Products

20 competing products in Infection, Human Immunodeficiency Virus I

See all competitors

Product	Company	Stage	Hype Score
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1944	Moderna	Phase 1	0
mRNA-1189	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1653	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1653	Moderna	Phase 1	0
mRNA-1195.1	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
DFA-02 Antibiotic Gel + DFA-02 Placebo Gel	Dr. Reddy's Laboratories	Phase 2	32
DFA-02 + Placebo	Dr. Reddy's Laboratories	Phase 1/2	29
Levofloxacin + Levofloxacin	Dr. Reddy's Laboratories	Approved	36
BSG005	Alkem Laboratories	Phase 1/2	39
Zotatifin + Placebo	eFFECTOR Therapeutics	Phase 1	19
AAVLP-HPV + Placebo	2A Pharma	Phase 1	19
CT-P59	Celltrion	Phase 1	29
CT-P63 + Placebo	Celltrion	Phase 1	29